Indeed, in addition to AZD, the CHK1 inhibitors tested in this work (i.e., MK, Prexa, and GDC-0575—GDC) induce ERα degradation and prevent the proliferation of ET-resistant and ET-sensitive BC cell lines. The gene discussed is CHEK1; the disease is breast cancer.